Motivation: Large-scale publicly available genomic data on many disease phenotypes could improve our understanding of the molecular basis of disease. Tools that undertake this challenge by jointly analyzing multiple phenotypes are needed. Results: ADEPTUS is a web-tool that enables various functional genomics analyses based on a high-quality curated database spanning >38, 000 gene expression profiles and >100 diseases. It offers four types of analysis. (i) For a gene list provided by the user it computes disease ontology (DO), pathway, and gene ontology (GO) enrichment and displays the genes as a network. (ii) For a given disease, it enables exploration of drug repurposing by creating a gene network summarizing the genomic events in it. (iii) For a gene of interest, it generates a report summarizing its behavior across several studies. (iv) It can predict the tissue of origin and the disease of a sample based on its gene expression or its somatic mutation profile. Such analyses open novel ways to understand new datasets and to predict primary site of cancer. Availability and implementation:
Introduction
Case-control studies seek discriminatory signals between different phenotypes, in order to decipher the molecular basis of disease. Most analyses address a small number of studies, spanning very few phenotypes and tissues and a modest number of samples. These limitations reduce the reliability and specificity of disease data analysis. We introduce ADEPTUS, a new web-tool that aims to overcome these issues by conducting analyses based on multiple diseases and numerous studies simultaneously. It employs a novel high quality database of >37 000 gene expression profiles and >9500 cancer somatic mutation profiles, covering >200 different disease and tissues. We developed a classifier that gave high quality predictions for 68 of the disease and tissue labels. Good predictors produced biomarkers that were scored for replicability, intensity, and specificity. ADEPTUS uses these results for diverse functional analyses, including disease and function enrichment of gene sets, network analysis of a disease, and disease label prediction (Fig. 1A) .
Materials and methods

The gene expression database
We assembled and manually annotated 37 337 gene expression profiles. Each profile was annotated with the tissue of origin and either with a set of disease ontology (DO) terms or as a control. The label Applications Note of a profile is a phenotype of a disease, a tissue, or both. For example, melanoma, skin, and melanoma of skin are all labels. The profiles cover 10, 501 genes that were shared across all samples, 190 disease labels and 18 tissue labels. Using this database we performed for each label and gene a conservative leave-study-out cross validation (Amar et al., 2015) , obtaining three scores for label-gene association: signal strength and specificity (computed using ROC, default threshold: 0.7), and replicability (computed using meta-analysis over the datasets, default threshold-value: 0.01; >50% P-values < 0.05 was defined as replicated signal). See the Supplementary Material for details. Sixty-eight labels passed all thresholds. Those were defined as well-classified and used for subsequent analyses.
Analysis of a gene list
Users can upload a gene list and perform several enrichment analyses: (i) gene ontology (GO) enrichments, computed using TANGO (Ulitsky et al., 2010) , (ii) pathway enrichment, computed using Fisher's exact test on KEGG (Kanehisa and Goto, 2000) and WikiPathways (Kelder et al., 2012) pathways and (iii) DO enrichment, using a gene set enrichment analysis (GSEA) -like analysis (Subramanian et al., 2005) . To the best of our knowledge, this is the first tool to provide disease enrichment.
Analysis of a disease
For each well-classified label the tool displays its biomarker genes in a summary network. Nodes are genes and edges are protein or genetic interactions taken from GeneMANIA (Montojo et al., 2014) . Color-coding of the gene's node gives information on it: up-or down-regulation compared to the negatives or the background, and availability of a drug targeting the gene (Law et al., 2014) . For cancer labels, a color indicates when the gene is associated with the label based on somatic mutation data (Amar et al., 2017) . The set of genes displayed can be changed by adjusting score thresholds.
Analysis of new profiles
Our classifiers (for the well-classified labels) can be applied on new profiles. Given an input matrix of patients Â profiles (gene expression or mutated genes), the classifiers output a table of patients Â labels, whose values are the predicted association probabilities.
Given a list of mutated genes in a biopsy, we predict the cancer subtype (e.g. the primary cancer of a metastasis sample) using our multi-label classifiers (Amar et al., 2017) .
Results
We analyzed melanoma, the most lethal and treatment-resistant human skin cancer, for which new treatment and prevention approaches are needed (Hodis et al., 2012) . The ADEPTUS database had three relevant labels: melanoma, skin melanoma, and uveal melanoma. Only melanoma was well-classified, mainly because no reliable classifier distinguished between skin and uveal melanoma. Melanocytes, the melanoma origin cells, are specialized in releasing pigment vesicles, termed melanosomes (Raposo and Marks, 2007) . Melanoma keeps this ability in order to directly affect the formation of their tumor niche by microRNA trafficking via melanosomes (Dror et al., 2016) . Remarkably, ADEPTUS selected genes (Fig. 1B) that were enriched for vesicles transport and pigmentation (q < 1e-03). When we compared melanoma to other diseases by increasing the specificity score to 0.9 (Fig. 1C) , melanoma vesicles were again found as the most significant GO enrichment. Dror et al. (2016) further found that inhibition of melanosome trafficking by melanoma can block melanoma formation. ADEPTUS offered new drug targets ( Fig. 1B and C) with promising therapeutic potential to block melanosome trafficking in addition to the drug used in (3). Taken together, ADEPTUS is a strong tool for identifying disease related genes and for proposing new potential drugs. Conflict of Interest: none declared. 
